A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer

NCT01130142 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: IPI-926 plus gemcitabine
DRUG: Placebo plus gemcitabine

Sponsor

Infinity Pharmaceuticals, Inc.